Galecto, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
GLTO Nasdaq 2834 galecto.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galecto, Inc.

Galecto Reports Full-Year 2024 Financial Results - Mar 19th, 2025 8:45 pm
Galecto to Participate in Upcoming Investor Conferences - Feb 6th, 2025 1:00 pm
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nov 14th, 2024 2:55 pm
Galecto Reports Third Quarter 2024 Financial Results - Nov 1st, 2024 12:30 pm
Galecto price target raised to $10 from $9 at Oppenheimer - Oct 18th, 2024 12:15 pm
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - Oct 15th, 2024 12:30 pm
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines - Oct 7th, 2024 12:45 pm
Galecto Announces Reverse Stock Split - Aug 28th, 2024 1:00 pm
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab - May 1st, 2024 8:01 pm